FDA Grants Fast Track Status to OnCusp's Novel Antibody-Drug Conjugate for Platinum-Resistant Ovarian Cancer
• The FDA has awarded Fast Track Designation to CUSP06, an innovative Cadherin-6 targeting Antibody-Drug Conjugate developed by OnCusp Therapeutics for platinum-resistant ovarian cancer treatment.
• Early Phase 1 trial results demonstrate promising anti-tumor activity and manageable safety profile for CUSP06 in patients with platinum-refractory/resistant ovarian cancer.
• This regulatory milestone will accelerate the development process, potentially bringing a new therapeutic option to an underserved patient population more quickly.
© Copyright 2025. All Rights Reserved by MedPath